Literature DB >> 21247526

Achieving optimal lipid goals in patients with coronary artery disease.

Dean G Karalis1, Raghunandan Dudda Subramanya, Scott E Hessen, Longjian Liu, Mark F Victor.   

Abstract

Guidelines for lipid-lowering therapy recommend intensive low-density lipoprotein (LDL) cholesterol lowering for patients with coronary artery disease. Previous studies have found that many high-risk patients are not achieving their LDL cholesterol goals, and many patients, despite being treated with lipid-lowering therapy, also have elevated triglycerides or low levels of high-density lipoprotein (HDL) cholesterol. To evaluate lipid goals in a "real world" clinical setting, the electronic medical records of 10,040 patients with coronary artery disease from a large cardiology subspecialty practice from September 2008 to September 2009 were reviewed. Overall, 79% of patients achieved an LDL cholesterol goal of <100 mg/dl, while only 35% achieved the more aggressive goal of <70 mg/dl. Non-HDL cholesterol goals of <130 and <100 mg/dl were achieved in 79% and 44% of patients, respectively. Only 69% achieved normal triglyceride levels, and only 63% of men and 56% of women achieved normal levels of HDL cholesterol. Women and younger men were less likely to achieve their lipid goals. In conclusion, most patients with coronary artery disease achieve the minimal LDL cholesterol goal of 100 mg/dl, but few achieve the more aggressive goals of <70 mg/dl. Many high-risk patients have elevated levels of triglycerides or low levels of HDL cholesterol despite treatment. Combination lipid-lowering therapy is used infrequently in practice. There exists a significant opportunity for physicians to more aggressively treat lipids to achieve the levels recommended by clinical guidelines.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21247526     DOI: 10.1016/j.amjcard.2010.11.006

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  15 in total

1.  Lipid-Lowering Prescription Patterns in Patients With Diabetes Mellitus or Cardiovascular Disease.

Authors:  Alanna M Chamberlain; Sarah S Cohen; Jill M Killian; Keri L Monda; Susan A Weston; Ted Okerson
Journal:  Am J Cardiol       Date:  2019-07-15       Impact factor: 2.778

2.  Management of atherosclerosis risk factors for patients at high cardiovascular risk in real-world practice: a multicentre study.

Authors:  Arintaya Phrommintikul; Rungroj Krittayaphong; Wanwarang Wongcharoen; Sukit Yamwong; Smonporn Boonyaratavej; Rapeephon Kunjara-Na-Ayudhya; Pyatat Tatsanavivat; Piyamitr Sritara
Journal:  Singapore Med J       Date:  2017-05-25       Impact factor: 1.858

3.  Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets (IMPACT) trial.

Authors:  Eugenia Gianos; Antoinette Schoenthaler; Yu Guo; Judy Zhong; Howard Weintraub; Arthur Schwartzbard; James Underberg; Michael Schloss; Jonathan D Newman; Sean Heffron; Edward A Fisher; Jeffrey S Berger
Journal:  Am Heart J       Date:  2018-01-09       Impact factor: 4.749

4.  Effect of gender, caregiver, on cholesterol control and statin use for secondary prevention among hospitalized patients with coronary heart disease.

Authors:  Gmerice Hammond; Heidi Mochari-Greenberger; Ming Liao; Lori Mosca
Journal:  Am J Cardiol       Date:  2012-08-15       Impact factor: 2.778

5.  Lipid targets in clinical practice: successes, failures and lessons to be learned.

Authors:  M Dunne; O Mac Ananey; C Markham; V Maher
Journal:  Ir J Med Sci       Date:  2013-04-25       Impact factor: 1.568

6.  How can we further improve the LDL-cholesterol target level achievement rate based on the Hungarian MULTI GAP 2011 study results and considering the new European dyslipidemia guidelines?

Authors:  Laszlo Mark; György Paragh; Istvan Karadi; Istvan Reiber; Gyula Pados; Zoltan Kiss
Journal:  Arch Med Sci       Date:  2012-09-08       Impact factor: 3.318

7.  The Lipid-lowering Effects of R-bambuterol in Healthy Chinese Volunteers: A Randomized Phase I Clinical Study.

Authors:  Yanrui Ye; Hang Xu; Lei Quan; Long Zhu; Jing Zeng; Ting Zhou; ChengJuan Zou; Qing Cheng; Shujie Bu; Wen Tan
Journal:  EBioMedicine       Date:  2015-02-13       Impact factor: 8.143

8.  Low-density lipoprotein cholesterol of less than 70 mg/dL is associated with fewer cardiovascular events in acute coronary syndrome patients: a real-life cohort in Thailand.

Authors:  Dujrudee Chinwong; Jayanton Patumanond; Surarong Chinwong; Khanchai Siriwattana; Siriluck Gunaparn; John Joseph Hall; Arintaya Phrommintikul
Journal:  Ther Clin Risk Manag       Date:  2015-04-24       Impact factor: 2.423

9.  Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients.

Authors:  Dean G Karalis; Brett Victor; Lilian Ahedor; Longjian Liu
Journal:  Cholesterol       Date:  2012-07-25

10.  Evaluating quality and its determinants in lipid control for secondary prevention of heart disease and stroke in primary care: a study in an inner London Borough.

Authors:  Hiten Dodhia; Liu Kun; Hugh Logan Ellis; James Crompton; Anthony S Wierzbicki; Helen Williams; Anna Hodgkinson; John Balazs
Journal:  BMJ Open       Date:  2015-12-09       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.